After decriminalizing minor cannabis possession in 2012, Switzerland has made several advancements in developing progressive laws around cannabis and CBD. By legalizing sales of low-THC cannabis and CBD, it has positioned itself as an obvious and attractive option for domestic and international businesses looking to enter the European market.
While, medical cannabis remains surprisingly limited—with only two pharmacies licensed to dispense tinctures and oil concentrates to patients with serious or terminal illnesses—the government recently approved a pilot program to start cannabis trials for recreational use. With approximately 20,0000 cannabis users in Switzerland, the recreational market is estimated to be worth $500 million.
This panel aims to give a detailed overview on the future of the Swiss cannabis and CBD markets.
Host: Paul Rosen, Executive Chairman, Global Go
Keynote: Peter Steger Owner Of Heidak Ag And Spagyrik Produktions Ag
Andrew Petronanos Founder, Fineleaf and Global Go Switzerland
Dr. Sandra Schoenes Founder & Director, Heidi’s Garden & Reyos
Roger Koch CEO and Founder of HEIMAT
Yannik Schlup CSO at PureGene and PURE Holding AG
Dr Gian Trepp Founder of GBTPharma and commercial director of Creso Pharma